ArticleFrontiers in immunology2026
Fresh ginseng-derived vesicle-like nanoparticles protect against intestinal barrier injury in inflammatory bowel disease via the miR-29a-5p/TLR4 axis.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Inflammatory bowel disease (IBD) remains therapeutically challenging, and disruption of the intestinal epithelial barrier constitutes a key pathogenic event. Ginseng-derived vesicle-like nanoparticles (GDNPs) protect against intestinal barrier injury in IBD; however, the effects of ginseng processing on nanoparticle characteristics and biological activity remain insufficiently understood. Methods: The protective effect of fresh and dried ginseng extract were compared in IBD model. GDNPs were isolated from fresh and dried ginseng by differential centrifugation and sucrose density-gradient ultracentrifugation, and characterized for morphology, particle size, and relative purity. Their effects on intestinal epithelial cell viability and permeability were compared. Results: Both fresh and dried ginseng extracts alleviated DSS-induced intestinal injury, with fresh ginseng extract showing stronger protective effects in several pathological and inflammatory parameters. Fresh and dried GDNPs showed comparable spherical morphology and particle-to-protein ratios, but fresh GDNPs were more susceptible to Triton X-100-induced lysis, indicating a higher proportion of intact vesicles. Fresh GDNPs promoted intestinal epithelial cell viability, whereas dried GDNPs at the same concentration had no significant effect, and fresh GDNPs conferred stronger protection against epithelial permeability disruption. In inflamed epithelial and macrophage models, fresh GDNPs suppressed TLR4/STAT3 signaling and pro-inflammatory cytokines (IL-6, IL-1β, TNF-α) while restoring tight junction proteins (Occludin, Claudin-1) and miR-29a-5p expression. Mechanistically, fresh GDNPs preserved epithelial barrier integrity by upregulating miR-29a-5p, which directly targeted and suppressed TLR4, and by reprogramming the macrophage inflammatory secretome. In DSS-induced colitis, fresh GDNPs attenuated body weight loss, DAI scores, and colon shortening; reduced M1 macrophage polarization; preserved tight junction protein expression; and restored miR-29a-5p expression in colon tissue. Conclusion: Fresh and dried ginseng-derived GDNPs exhibited differential epithelial protective effects
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.